Prostatype Genomics

Prostatype Genomics Rule of 40

The Rule of 40 of Prostatype Genomics (PROGEN.ST) as of Oct 28, 2026 is -6,380.63 %. In the previous year, Rule of 40 was -20,614.47 % — a change of -69.05% (higher).

Rule of 40

-6,380.63 %

YoY

-69.05%

Last updated:

Rule of 40 of Prostatype Genomics is 2025 -6,380.63 % . Rule of 40 of Prostatype Genomics was 2024 -20,614.47 % . It decreases by -69.05% higher compared to the previous year.

The Prostatype Genomics Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2016
4,729.10 SEK
Jan 1, 2017
-5,757.24 SEK
Jan 1, 2018
-10,665.93 SEK
Jan 1, 2021
-155,581.19 SEK
Jan 1, 2022
2,529.41 SEK
Jan 1, 2023
-2,795.79 SEK
Jan 1, 2024
-20,614.47 SEK
Jan 1, 2025
-6,380.63 SEK
The Prostatype Genomics Rule of 40 history
YEARRule of 40YoY
-6,380.63 %-69.05%
-20,614.47 %+637.34%
-2,795.79 %-210.53%
2,529.41 %-101.63%
-155,581.19 %+1,358.67%
-10,665.93 %+85.26%
-5,757.24 %-221.74%
4,729.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Rule of 40 of Prostatype Genomics is -6,380.63 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Prostatype Genomics

All Key Metrics — Prostatype Genomics